Next Generation Sequencing Facilitates Quantitative Analysis of human umbilical vein endothelial cell(HUVEC) with and without treatment of CHIR99021+FGF1

The mortality of patients suffering from acute myocardial infarction (AMI) is linearly related to the infarct size. As regeneration of cardiomyocytes from cardiac progenitor cells is minimal in the mammalian adult heart, we have explored a new therapeutic approach which leverages the capacity of nanomaterials to release chemicals over time to promote myocardial protection and infarct size reduction. Initial screening identified two chemicals, FGF1 and CHIR99021 (a Wnt1 agonist/GSK-3 antagonist) which synergistically enhance cardiomyocyte cell cycle in vitro. Poly-lactic-co-glycolic acid (PLGA) nanoparticles (NP) formulated with CHIR99021 and FGF1 (CHIR+FGF1-NPs) provided an effective slow release system for up to 4 weeks. Intramyocardial injection of CHIR+FGF1-NPs enabled myocardial protection via reducing infarct size by 20-30% in mouse or pig models of postinfarction LV remodeling. This LV structural improvement was accompanied by a significant preservation of cardiac contractile function. Further investigation revealed that CHIR+FGF1-NPs resulted in a significant reduction of cardiomyocyte apoptosis and increase of angiogenesis. Thus, using a combination of chemicals and a NP-based prolonged release system that work synergistically, this study demonstrates a novel therapy for LV infarct size reduction in hearts with acute myocardial infarction. Overall design: Examination of 2 different treatment in HUVECs. Total cellular RNA was isolated from CHIR+FGF1 (5 µM, 100 ng/ml, respectively)-treated and control HUVECs and subjected to next generation RNA sequencing (RNA-Seq). The mRNA profiles indicated that 815 genes out of 18845 genes (adjusted p < 0.05) showed significant changes in their expression levels. The relative mRNA expression profile of various representative genes related to angiogenesis, cell proliferation, cell senescence and death were examined.